Complete AAV Production System Enables Scalable Gene Therapy Workflows

CARLSBAD, Calif., September 20, 2021 /PRNewswire/ — Responding to the need to make adeno-associated virus (AAV) production more efficient and scalable, Thermo Fisher Scientific has launched the Gibco AAV-MAX* Integrated Unaided AAV Production System, a complete and that simplifies the AAV vector production workflow. The all-in-one AAV-MAX system increases productivity and profitability by delivering high viral titers using Viral Production Cells 2.0, a new clonally documented 293F-derived mammalian cell line.

AAV is crucial in the field of gene therapy; more than 1,300 unique gene therapy products are currently in development, and almost half rely on AAV. The ability to scale production is key to reducing costs and accelerating the process from research to commercialization.

“AAV has an efficacy and safety profile that makes it an ideal therapeutic vector and one of the go-to biological delivery methods for the latest advances in gene therapy,” said Amy Butler, President, Biosciences, Thermo Fisher Scientific. “AAV’s new production system is part of our end-to-end workflow solutions designed to meet the growing demand for cost-effective and scalable viral vector production. Having access to products and services designed specifically for research in cell and gene therapy, with a range of views to clinical manufacturing, strengthens our biotechnology and biopharmaceutical partners.”

The AAV-MAX system was developed to go from shake flasks to bioreactors. Coupled with the active development of regulatory-compliant reagents**, the system is designed to streamline the transition from research to commercial manufacturing. On average, the system can save researchers and viral vector developers 25% on plasmid DNA usage and 50% on production costs compared to polyethyleneimine-based mammalian production systems ( IEP). When used in conjunction with Thermo Fisher’s expanded portfolio of gene therapy products, developers are able to smoothly transition to commercial production to facilitate the delivery of therapies to patients.

To learn more about Thermo Fisher’s AAV Workflow Solutions, please visit www.thermofisher.com/aav. To learn more about the Gibco AAV-MAX Unaided AAV Production System, please visit www.thermofisher.com/aavmax.

* For research purposes only.
** cGMP will be available with the Cell Therapy Systems (CTS) AAV-MAX production system.

About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with annual sales of approximately $35 billion. Our mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life science research, solving complex analytical challenges, improving patient diagnostics and therapies, or increasing their lab productivity, we’re here to support them. Our global team of more than 90,000 colleagues delivers an unparalleled combination of innovative technology, purchasing convenience and pharmaceutical services through our industry-leading brands including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services and Patheon. For more information, visit www.thermofisher.com.

Media Contacts:

Mauricio Minotta
Phone: 760-805-5266
E-mail: [email protected]

jessica parry
Phone: 419-266-4016
E-mail: [email protected]

SOURCEThermo Fisher Scientific

Related links

http://www.thermofisher.com